NCT06895382

Brief Summary

This randomized controlled trial investigates the postoperative analgesic efficacy of caudal epidural block versus ultrasound-guided transversus abdominis plane (TAP) block in pediatric patients undergoing infraumbilical surgery. A total of 60 pediatric patients (aged 1 to 7 years, ASA I-II) were randomly assigned to one of two groups:

  • Group C (Caudal Block): Received 1 mL/kg of 0.25% bupivacaine in the caudal epidural space.
  • Group T (TAP Block): Received 0.3 mL/kg of 0.25% bupivacaine injected into the transversus abdominis plane under ultrasound guidance. Primary Outcome:
  • Postoperative FLACC pain scores at 2, 6, 12, and 24 hours. Secondary Outcomes:
  • Total analgesic consumption (including rescue analgesia).
  • Intraoperative hemodynamic parameters (heart rate, blood pressure, SpO₂).
  • Incidence of nausea and vomiting (PONV).
  • Parental satisfaction scores. The study aims to determine which regional anesthesia technique provides superior pain relief and reduces systemic analgesic requirements in pediatric patients.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
60

participants targeted

Target at P25-P50 for not_applicable postoperative-pain

Timeline
Completed

Started Dec 2022

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

December 15, 2022

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 15, 2023

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 15, 2023

Completed
1.3 years until next milestone

First Submitted

Initial submission to the registry

March 19, 2025

Completed
7 days until next milestone

First Posted

Study publicly available on registry

March 26, 2025

Completed
Last Updated

April 1, 2025

Status Verified

March 1, 2025

Enrollment Period

1 year

First QC Date

March 19, 2025

Last Update Submit

March 26, 2025

Conditions

Keywords

Caudal Epidural BlockTransversus Abdominis Plane BlockPediatric Pain Management

Outcome Measures

Primary Outcomes (1)

  • Postoperative FLACC Pain Scores

    Postoperative pain intensity was measured using the Face, Legs, Activity, Cry, Consolability (FLACC) scale at predefined time points after surgery. The FLACC scale is a validated tool for assessing postoperative pain in pediatric patients based on behavioral observations.

    FLACC pain scores were recorded at 2, 6, 12, and 24 hours postoperatively

Secondary Outcomes (4)

  • Total Postoperative Analgesic Consumption

    0-24 hours postoperatively

  • Intraoperative Hemodynamic Stability

    Baseline, after induction, after surgical incision, and at 15, 30, 45, and 60 minutes intraoperatively.

  • Incidence of Postoperative Nausea and Vomiting (PONV)

    0-24 hours postoperatively

  • Parental Satisfaction Scores

    Recorded at 24 hours postoperatively and at a follow-up phone call after discharge.

Study Arms (2)

Group C - Caudal Epidural Block

EXPERIMENTAL

Participants in this group received a caudal epidural block after the induction of general anesthesia. A 35-mm 22G or 30-mm 25G block needle was inserted through the sacrococcygeal ligament into the epidural space under aseptic conditions. After confirming negative aspiration for cerebrospinal fluid or blood, 1 mL/kg of 0.25% bupivacaine was administered.

Procedure: Caudal Epidural BlockDrug: Bupivacaine 0.25%

Group T - Transversus Abdominis Plane (TAP) Block

EXPERIMENTAL

Participants in this group received an ultrasound-guided transversus abdominis plane (TAP) block after the induction of general anesthesia. A 22G, 50-mm insulated block needle was inserted using an in-plane technique under ultrasound guidance with a linear probe. The needle was advanced into the fascial plane between the internal oblique and transversus abdominis muscles. After confirming placement with a 0.5-1 mL test dose of 0.9% NaCl and negative aspiration for blood, 0.3 mL/kg of 0.25% bupivacaine was administered.

Procedure: Transversus Abdominis Plane (TAP) BlockDrug: Bupivacaine 0.25%

Interventions

A caudal epidural block was performed after the induction of general anesthesia. Using a 35-mm 22G or 30-mm 25G block needle, the sacral hiatus was identified, and the needle was inserted through the sacrococcygeal ligament into the epidural space under aseptic conditions. After confirming negative aspiration for cerebrospinal fluid or blood, 1 mL/kg of 0.25% bupivacaine was administered.

Also known as: Caudal Block, Caudal Anesthesia
Group C - Caudal Epidural Block

A transversus abdominis plane (TAP) block was performed after the induction of general anesthesia. Using a 22G, 50-mm insulated block needle, the injection was administered under ultrasound guidance using a linear probe and in-plane technique. The needle was advanced into the fascial plane between the internal oblique and transversus abdominis muscles. After confirming placement with a 0.5-1 mL test dose of 0.9% NaCl and negative aspiration for blood, 0.3 mL/kg of 0.25% bupivacaine was administered.

Also known as: TAP Block, Ultrasound-Guided TAP Block
Group T - Transversus Abdominis Plane (TAP) Block

0.25% bupivacaine was administered in both intervention arms as part of the regional anesthesia procedure In the Caudal Block group, 1 mL/kg of 0.25% bupivacaine was administered into the caudal epidural space. In the TAP Block group, 0.3 mL/kg of 0.25% bupivacaine was administered into the transversus abdominis plane under ultrasound guidance

Group C - Caudal Epidural BlockGroup T - Transversus Abdominis Plane (TAP) Block

Eligibility Criteria

Age1 Year - 7 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)

You may qualify if:

  • Pediatric patients aged 1 to 7 years.
  • ASA Physical Status I-II.
  • Undergoing infraumbilical abdominal surgery (e.g., hernia repair, orchiopexy, circumcision).
  • Parental written informed consent obtained.

You may not qualify if:

  • Contraindications to regional anesthesia, such as:
  • Coagulopathy or bleeding disorders.
  • Local infection at the injection site.
  • Known allergy to local anesthetics.
  • Neurological conditions (e.g., degenerative neuropathy, brain tumors, increased intracranial pressure).
  • Intellectual disabilities affecting pain assessment.
  • Chronic pain conditions or opioid use before surgery.
  • Parental refusal to participate in the study.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Tekirdag Namik Kemal University

Tekirdağ, Turkey (Türkiye)

Location

MeSH Terms

Conditions

Pain, Postoperative

Interventions

Anesthesia, CaudalDental Occlusion

Condition Hierarchy (Ancestors)

Postoperative ComplicationsPathologic ProcessesPathological Conditions, Signs and SymptomsPainNeurologic ManifestationsSigns and Symptoms

Intervention Hierarchy (Ancestors)

Anesthesia, EpiduralAnesthesia, ConductionAnesthesiaAnesthesia and AnalgesiaDentistryDental Physiological PhenomenaDigestive System and Oral Physiological Phenomena

Study Officials

  • Onur Baran

    Namik Kemal University

    STUDY CHAIR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Masking Details
The study was single-blinded, with postoperative pain assessors blinded to the group allocation. The anesthesiologist administering the block was aware of the group assignment, but postoperative evaluators were not.
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: This study compares two regional anesthesia techniques for postoperative analgesia in pediatric patients undergoing infraumbilical surgery. Participants were randomized into two groups: Group C (Caudal Block) and Group T (TAP Block). Pain scores, analgesic consumption, and adverse effects were compared.
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

March 19, 2025

First Posted

March 26, 2025

Study Start

December 15, 2022

Primary Completion

December 15, 2023

Study Completion

December 15, 2023

Last Updated

April 1, 2025

Record last verified: 2025-03

Data Sharing

IPD Sharing
Will not share

Locations